CF PHARMTECH Shares Climb Over 4% Pre-Market as IND Application for Novel Drug ICF004 Accepted

Deep News02-25 11:30

CF PHARMTECH (02652) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.16%, trading at HK$38.52, with a turnover of HK$138.64 million.

On February 24, CF PHARMTECH announced that the Investigational New Drug application for its self-developed dry powder inhaler candidate drug, ICF004, has been accepted by the National Medical Products Administration. The acceptance of this application marks a significant milestone in the company's innovative drug development process and further demonstrates the transformative potential of its complex respiratory formulation and precision delivery platform.

It is understood that ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease, a therapeutic area covering severe conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which pose significant threats to patient survival. Targeting the unmet needs in PF-ILD, the development rationale for ICF004 is based on addressing the clinical dilemma of balancing efficacy and tolerability. The drug aims to explore new delivery and mechanism pathways beyond existing treatments, with the goal of improving the therapeutic window and patient benefits.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148572483?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 11:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148572483","market":"sh","top_or_hot":-1,"title":"CF PHARMTECH Shares Climb Over 4% Pre-Market as IND Application for Novel Drug ICF004 Accepted","media":"Deep News","content":"<p>CF PHARMTECH (02652) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.16%, trading at HK$38.52, with a turnover of HK$138.64 million.</p>\n<p>On February 24, CF PHARMTECH announced that the Investigational New Drug application for its self-developed dry powder inhaler candidate drug, ICF004, has been accepted by the National Medical Products Administration. The acceptance of this application marks a significant milestone in the company's innovative drug development process and further demonstrates the transformative potential of its complex respiratory formulation and precision delivery platform.</p>\n<p>It is understood that ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease, a therapeutic area covering severe conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which pose significant threats to patient survival. Targeting the unmet needs in PF-ILD, the development rationale for ICF004 is based on addressing the clinical dilemma of balancing efficacy and tolerability. The drug aims to explore new delivery and mechanism pathways beyond existing treatments, with the goal of improving the therapeutic window and patient benefits.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PHARMTECH Shares Climb Over 4% Pre-Market as IND Application for Novel Drug ICF004 Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PHARMTECH Shares Climb Over 4% Pre-Market as IND Application for Novel Drug ICF004 Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-02-25 11:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PHARMTECH (02652) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.16%, trading at HK$38.52, with a turnover of HK$138.64 million.</p>\n<p>On February 24, CF PHARMTECH announced that the Investigational New Drug application for its self-developed dry powder inhaler candidate drug, ICF004, has been accepted by the National Medical Products Administration. The acceptance of this application marks a significant milestone in the company's innovative drug development process and further demonstrates the transformative potential of its complex respiratory formulation and precision delivery platform.</p>\n<p>It is understood that ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease, a therapeutic area covering severe conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which pose significant threats to patient survival. Targeting the unmet needs in PF-ILD, the development rationale for ICF004 is based on addressing the clinical dilemma of balancing efficacy and tolerability. The drug aims to explore new delivery and mechanism pathways beyond existing treatments, with the goal of improving the therapeutic window and patient benefits.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1148572483","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148572483","pubTimestamp":1771990244,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"CF PHARMTECH (02652) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.16%, trading at HK$38.52, with a turnover of HK$138.64 million. On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业","BK1191":"制药"},"translate_title":"新药ICF004 IND申请获批，CF PHARMTECH股价盘前上涨逾4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PHARMTECH (02652) saw its shares rise more than 5% during the trading session. As of the time of writing, the stock was up 4.16%, trading at HK$38.52, with a turnover of HK$138.64 million.\nOn February 24, CF PHARMTECH announced that the Investigational New Drug application for its self-developed dry powder inhaler candidate drug, ICF004, has been accepted by the National Medical Products Administration. The acceptance of this application marks a significant milestone in the company's innovative drug development process and further demonstrates the transformative potential of its complex respiratory formulation and precision delivery platform.\nIt is understood that ICF004 is intended for the treatment of progressive fibrosing interstitial lung disease, a therapeutic area covering severe conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, which pose significant threats to patient survival. Targeting the unmet needs in PF-ILD, the development rationale for ICF004 is based on addressing the clinical dilemma of balancing efficacy and tolerability. The drug aims to explore new delivery and mechanism pathways beyond existing treatments, with the goal of improving the therapeutic window and patient benefits.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148572483","isCrawlerRequest":true}